[go: up one dir, main page]

NO20004491L - Blanding - Google Patents

Blanding

Info

Publication number
NO20004491L
NO20004491L NO20004491A NO20004491A NO20004491L NO 20004491 L NO20004491 L NO 20004491L NO 20004491 A NO20004491 A NO 20004491A NO 20004491 A NO20004491 A NO 20004491A NO 20004491 L NO20004491 L NO 20004491L
Authority
NO
Norway
Prior art keywords
disease
alzheimer
mixture
dementia
mammals
Prior art date
Application number
NO20004491A
Other languages
English (en)
Other versions
NO20004491D0 (no
Inventor
Robert Glinecke
William Muldoon
Joseph Sauer
Susan Marie Milosovich
Laurence Rosseau
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9805192.3A external-priority patent/GB9805192D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO20004491L publication Critical patent/NO20004491L/no
Publication of NO20004491D0 publication Critical patent/NO20004491D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

Doseformer med kontrollert frigjøring som er nyttige ved behandling og/eller forebygging av demens, omfattende Alzheimers sykdom, hos pattedyr og for å forbedre amyloid-forløperprotein-prosessering langs en ikke-amyloidogen bane hos pasienter som lider av eller med risiko for å utvikle, Alzheimers sykdom.
NO20004491A 1998-03-11 2000-09-08 Blanding NO20004491D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7748098P 1998-03-11 1998-03-11
US7752798P 1998-03-11 1998-03-11
GBGB9805192.3A GB9805192D0 (en) 1998-03-11 1998-03-11 Composition
PCT/EP1999/001557 WO1999045924A1 (en) 1998-03-11 1999-03-05 Composition

Publications (2)

Publication Number Publication Date
NO20004491L true NO20004491L (no) 2000-09-08
NO20004491D0 NO20004491D0 (no) 2000-09-08

Family

ID=27269240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004491A NO20004491D0 (no) 1998-03-11 2000-09-08 Blanding

Country Status (16)

Country Link
US (1) US6451343B1 (no)
EP (1) EP1061918A1 (no)
JP (1) JP2002506031A (no)
KR (1) KR20010034588A (no)
CN (1) CN1292696A (no)
AR (1) AR018147A1 (no)
AU (1) AU748396C (no)
CA (1) CA2323177A1 (no)
CO (1) CO5080740A1 (no)
HU (1) HUP0101043A3 (no)
IL (1) IL138192A0 (no)
NO (1) NO20004491D0 (no)
NZ (1) NZ505807A (no)
PL (1) PL342600A1 (no)
TR (1) TR200002626T2 (no)
WO (1) WO1999045924A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2813651B1 (fr) 2000-09-05 2004-06-11 Valeo Appareil d'accouplement hydrocinetique, notamment pour vehicule automobile
BR0215262A (pt) * 2001-12-20 2004-12-28 Pharmacia Corp Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
JP4757872B2 (ja) 2004-08-13 2011-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20080014257A1 (en) * 2006-07-14 2008-01-17 Par Pharmaceutical, Inc. Oral dosage forms
US9290759B2 (en) * 2010-08-25 2016-03-22 The Trustees Of Columbia University In The City Of New York Optimized miRNA constructs
CA2992728A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
US11648242B2 (en) * 2019-12-12 2023-05-16 Aurobindo Pharma Ltd Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207444B (en) 1990-07-12 1993-04-28 Biorex Kutato Fejlesztoe Kft Method for producing therapeutical preparation suitable for treating alzheimer-disease
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (es) * 1995-07-29 1998-11-04 Smithkline Beecham Plc Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma.
GB9619074D0 (en) 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition

Also Published As

Publication number Publication date
EP1061918A1 (en) 2000-12-27
PL342600A1 (en) 2001-06-18
NZ505807A (en) 2003-01-31
TR200002626T2 (tr) 2001-03-21
WO1999045924A1 (en) 1999-09-16
AU748396C (en) 2003-01-23
AR018147A1 (es) 2001-10-31
HUP0101043A3 (en) 2002-02-28
AU3033299A (en) 1999-09-27
HUP0101043A2 (hu) 2001-12-28
AU748396B2 (en) 2002-06-06
CA2323177A1 (en) 1999-09-16
JP2002506031A (ja) 2002-02-26
KR20010034588A (ko) 2001-04-25
CN1292696A (zh) 2001-04-25
IL138192A0 (en) 2001-11-25
US6451343B1 (en) 2002-09-17
NO20004491D0 (no) 2000-09-08
CO5080740A1 (es) 2001-09-25

Similar Documents

Publication Publication Date Title
NO20004491L (no) Blanding
FI961438A7 (fi) beta-amyloidiproteiinituotannon estäjiä
NO20100061L (no) Forhindring og behandling av amyloidogen sykdom
Licastro et al. Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?
IS2925B (is) Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi
WO2004032868A3 (en) Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
PT1056856E (pt) Factor neurotrofico cliliar modificado processo de preparacao e sua utilizacao
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
DK1416965T3 (da) Assayfremgangsmåde til Alzheimers sygdom
NO20001869L (no) FremgangsmÕte for behandling av Alzheimers sykdom
Luo et al. Homocysteine induces τ hyperphosphorylation in rats
Kim et al. C-terminal fragment of Alzheimer's amyloid precursor protein inhibits sodium/calcium exchanger activity in SK-N-SH cell
NO993407L (no) Fremstilling av proteinpreparater med nedsatt aggregatinnhold
ATE251912T1 (de) Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
DK0786998T3 (da) Anvendelse af [R-(Z)]-alfa-(metoxyimino)-alfa-(1-azabicyclo[2.2.2]oct-3-yl)acetonitril til reduktion af amyloid-beta-A4-dannelse ved Alzheimer's sygdom
BR9908374A (pt) Composição
NO963347D0 (no) Fremgangsmåte for identifisering av individer som lider av en cellulær abnormitet
WO2002041839A3 (en) Assays for inhibitors of neuronal transport of alzheimer's amyloid precursor protein
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
WO2002055667A3 (en) Identification of an advanced sleep phase syndrome gene in humans
Kee Evaluation of Mood at Mental Status Examination in Geriatric Patients
Bushnell Alzheimer's disease and dementia: New insights
FR2778104B1 (fr) Utilisation d'un vecteur d'ions fluorure pour la preparation d'un medicament destine a la prevention ou au traitement de maladies associees a helicobacter pylori
SE9800359D0 (sv) Pharmaceutical preparation and method for treatment, prevention and diagnosis of gastrooesophageal reflux disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application